Trilostane 13647-35-3 | Veterinary Endocrine API Supplier

Trilostane: Competitive 3β-Hydroxysteroid Dehydrogenase Inhibitor

Trilostane is a synthetic steroid analog that reversibly inhibits the enzyme 3β-hydroxysteroid dehydrogenase, blocking the conversion of pregnenolone to progesterone and thereby reducing the synthesis of cortisol and other adrenal steroids. It is the first-line medical treatment for canine hyperadrenocorticism (Cushing’s disease).

Product Profile

CAS Number 13647-35-3
Molecular Formula C20H27NO3
Appearance White to off-white crystalline powder
Therapeutic Category Veterinary Adrenal Steroidogenesis Inhibitor
Storage Store at controlled room temperature

Applications

Trilostane is primarily used in veterinary medicine for the management of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs. Dosing is individualized based on ACTH stimulation test results, with regular monitoring required to avoid hypoadrenocorticism. It is formulated as oral capsules for dogs. In equine medicine, trilostane has been investigated for the management of equine metabolic syndrome. Historically, it was used in human medicine for Cushing’s syndrome and advanced breast cancer, though it has been largely replaced by newer agents in human therapeutics.

Why Source from TCS

TCS supplies trilostane to veterinary pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.

FAQ

What information should be included in an inquiry for Trilostane 13647-35-3?

A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.

How is Trilostane 13647-35-3 usually evaluated for sourcing?

This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.

What documentation and commercial points are commonly reviewed before buying Trilostane 13647-35-3?

For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.

Request a Quote

If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.

Contact the Commercial Team

Scroll to Top